Expression Levels of Interleukin 37 and Its Correlation With Autoantibodies and Disease Severity in Myasthenia Gravis Patients
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 82
- 主要终点
- Expression levels of Interleukin 37
研究概览
简要总结
Myasthenia gravis is a B-cell-mediated autoimmune disorders causing muscle weakness due to defective synaptic transmission at the neuromuscular junction caused by autoantibodies to acetylcholine receptors in (∼85%), muscle specific kinase in 6% and low-density lipoprotein receptor-related protein 4.The detection of these autoantibodies is very important not only in the diagnosis, but also for the stratification of Myasthenia Gravis patients into respective subgroups. These groups can differ in clinical manifestations, prognosis and response to therapies which become relevant for the development of antigen-specific therapies, targeting only the specific autoantibodies involved in the autoimmune response.
详细描述
Follicular T cells play a vital role during autoimmune disorders. The enhanced number or activation of these cells results in hyperproliferation of autoreactive B cells and overproduction of antibodies. Interleukin-37 is a newly identified immune-suppressive factor. It acts as an inhibitor of inflammation and plays an important regulatory role in both innate and adaptive immune responses. In Myasthenia Gravis, Cluster of differentiation 4+ T cell is the dominant cellular source for Interleukin-37 production directed to T follicular helper and B cells .It represses cell proliferation and secretion of autoantibody indicating that Interleukin-37 is a critical regulatory factor. The immunosuppressive features of Interleukin 37 contributing to autoimmune diseases are important and still poorly investigated. For this reason, the present study is designed to detect the level of expression of Interleukin 37 in Myasthenia Gravis patients and its correlation with autoantibodies serum levels and disease severity.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Clinical Diagnosis of Myasthenia Gravis.
- •Willingness to sample collection.
排除标准
- •History of chronic psychiatric or neurological disorder other than Myasthenia Gravis that can produce weakness or fatigue.
- •Severe systemic illness affecting life-expectancy ( chronic liver or kidney diseases).
- •History of autoimmune diseases, connective tissue diseases, , or genetic diseases.
- •Patients on large dosage of immune-suppressive treatment or Intravenous immunoglobulin in the recent 3 months.
结局指标
主要结局
Expression levels of Interleukin 37
时间窗: a year
change in the expression levels of Interleukin 37 gene in the Myasthenia Gravis patients relative to the healthy control.
次要结局
- Autoantibodies detection(a year)
研究者
Radwa Medhat Ahmed El Galaly
Demonstrator at Medical Microbiology and Immunology Department
Assiut University